ARMGO Pharma, Inc.
Edit

ARMGO Pharma, Inc.

http://www.armgo.com/
Last activity: 30.10.2023
Active
Categories: BioTechCauseDevelopmentDrugHumanMedtechResearch
ARMGO is a privately owned, venture-backed, biotech company that is developing small molecule drugs that repair leaky Ryanodine Receptor (RyR) calcium channels associated with human diseases. Our primary focus is on two orphan diseases: the life-threatening cardiac disease Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), and the severe muscle disease RYR1-Related Myopathy (RYR1-RM). These two conditions occur due to genetic mutations in the RYR gene: RYR1 in RYR1-RM, and RYR2 in most CPVT cases. ARMGO’s molecules, termed Rycals® are designed to repair leaky RyR channels. Since the cause of the symptoms is abnormal calcium leak due to these mutations, Rycals hold the promise of disease-modifying therapy for these two orphan genetic diseases.
Followers
95
Mentions
5
Location: United States, New York, Village of Ardsley
Employees: 1-10
Total raised: $35M
Founded date: 2006

Investors 3

Funding Rounds 1

DateSeriesAmountInvestors
20.12.2021Series B$35M-

Mentions in press and media 5

DateTitleDescription
03.01.2022Armgo Pharma Raises $35M in FundingArmgo Pharma, an Ardsley, New York-based novel small molecule therapeutics company developing treatments for cardiac, musculoskeletal, and neurological disorders, closed a $35m financing round. The round was led by Forbion with participatio...
21.12.2021ARMGO Pharma raises $35 million to progress clinical studies of lead molecule ARM210 in cardiac and skeletal muscle diseasesArdsley, NY – December 20, 2021 – ARMGO Pharma Inc (“ARMGO”), a leading novel small molecule therapeutics company developing treatments for cardiac, musculoskeletal, and neurological disorders today announced that it has completed a $35 mil...
20.12.2021Forbion leads $35M Series B for ARMGO PharmaAmsterdam, The Netherlands – 20th December 2021 – Forbion, a leading European life sciences venture capital firm, today announces that it has led a $35M series B financing in ARMGO Pharma Inc (“ARMGO”), a leading novel small molecule therap...
20.12.2021ARMGO Pharma raises $35 million to progress clinical studies of lead molecule ARM210 in cardiac and skeletal muscle diseasesARMGO Pharma raises $35 million to progress clinical studies of lead molecule ARM210 in cardiac and skeletal muscle diseases Series B investment led by Forbion and joined by Pontifax and Kurma Partners Investment will fund clinical studies ...
20.12.2021ARMGO Pharma raises $35 million to progress clinical studies of lead molecule ARM210 in cardiac and skeletal muscle diseasesARMGO Pharma raises $35 million to progress clinical studies of lead molecule ARM210 in cardiac and skeletal muscle diseases Series B investment led by Forbion and joined by Pontifax and Kurma Partners Investment will fund clinical studies ...

Reviews 0

Sign up to leave a review

Sign up Log In